title: Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.
abstract: The bivalent HPV16/18 vaccine induces high antibody concentrations in serum while data about antibody responses in the cervix are limited. In this study, we investigated pre- and post-vaccination antibody responses against seven high-risk HPV types by detection of IgG and IgA HPV-specific antibodies in cervical secretion samples (CVS) and serum. From an HPV vaccine monitoring study CVS and serum samples were available (pre-vaccination (n = 297), one year (n = 211) and two years (n = 141) post-dose-one vaccination) from girls aged 14-16 y. The girls were vaccinated with the bivalent HPV vaccine at months 0, 1 and 6. CVS was self-sampled using a tampon. Samples were tested for HPV-specific antibodies (HPV16/18/31/33/45/52/58) by a VLP-based multiplex immunoassay. Post-vaccination, IgG and IgA antibody levels for HPV16/18 were detectable in CVS and amounted to 2% and 1% of the IgG and IgA antibody levels observed in serum, respectively. The antibody levels remained constant between one and two years after vaccination. The correlation between CVS and serum was similar for IgG and IgA vaccine-derived antibody levels for HPV16 (rs = 0.58, rs = 0.54) and HPV18 (rs = 0.50, rs = 0.55). Vaccine-derived IgG antibody levels against cross-reactive HPV types in CVS and in serum were highest for HPV45. No IgA cross-reactive antibody responses could be detected in CVS. Post-vaccination, HPV16/18 IgG and IgA antibodies are not only detectable in serum but also in CVS. The correlation of HPV16/18 IgG antibody levels between serum and CVS suggests that vaccine induced HPV antibodies transudate and/or exudate from the systemic circulation to the cervical mucosa to provide protection against HPV infections.
authors.affiliation: Laboratory for Infectious Diseases and Screening; National Institute of Public Health and the Environment; Bilthoven, the Netherlands; Department of Pathology; VU University Medical Centre; Amsterdam, the Netherlands.
authors.forename: Mirte
authors.initials: M
authors.lastname: Scherpenisse
authors.forename: Madelief
authors.initials: M
authors.lastname: Mollers
authors.forename: Rutger M
authors.initials: RM
authors.lastname: Schepp
authors.forename: Chris J L M
authors.initials: CJ
authors.lastname: Meijer
authors.forename: Hester E
authors.initials: HE
authors.lastname: de Melker
authors.forename: Guy A M
authors.initials: GA
authors.lastname: Berbers
authors.forename: Fiona R M
authors.initials: FR
authors.lastname: van der Klis
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis* / Q000097:blood*; D012634:Bodily Secretions / Q000276:immunology; D005260:Female; D005836:Genitalia, Female / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007118:Immunoassay; D007070:Immunoglobulin A / Q000032:analysis*; D007074:Immunoglobulin G / Q000097:blood*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D044967:Serum / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D053918:Papillomavirus Vaccines